Clinical Trial 20069

• Overview

  Study Title:

  A PHASE 1/2, MULTI-CENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF AN ORALLY AVAILABLE SMALL MOLECULE, CC-99282, ALONE AND IN COMBINATION WITH ANTI-LYMPHOMA AGENTS IN SUBJECTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS (R/R NHL)

  Summary:

  The purpose of this study is to test the safety of the new experimental drug, CC-99282. For some participants with DLBCL or FL enrolling in Part B of the study, an additional purpose is to test the safety of CC-99282 in combination with rituximab.

  Objective:

  Primary Objectives: To determine the safety and tolerability of CC-99282 alone and in combination with rituximab in subjects with R/R NHL. To define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-99282 in subjects with R/R NHL. Secondary Objectives: To characterize the pharmacokinetics (PK) of CC-99282. To provide information on the preliminary efficacy of CC-99282 alone and in combination with rituximab in R/R NHL.

• Treatments

  Therapies:

  Therapy (NOS)

  Medications:

  CC-99282 (); EPZ-6438 (Tazemetostat); Obinutuzumab (); Rituxan (rituximab); Tazemetostat (); rituximab ()

• Inclusion Criteria

  • Participant is 18 years of age or older at the time of signing the informed consent form (ICF).
  • Participant has a history of NHL with relapsed or refractory disease.
  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
  • Participants must have the following laboratory values: (a) Absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L without growth factor support for 7 days (14 days if pegfilgrastim) (b) Hemoglobin (Hgb) greater than or equal to 8 g/dL (c) Platelets (plt) greater than or equal to 75 x 109/L without transfusion for 7 days (d) Serum bilirubin less than or equal to 1.5 x ULN (upper limit of normal). (e) AST/SGOT and ALT/SGPT less than or equal to 2.5X ULN (f) Estimated serum creatinine clearance of greater than or equal to 45 mL/min using the Cockcroft-Gault equation.
  • Agree to follow the CC-99282 Pregnancy Prevention Plan (PPP)
  • Other criteria may apply.

• Exclusion Criteria

  • Participant has life expectancy 2 months or less.
  • Participant has received prior systemic anti-cancer treatment (approved or investigational) less than or equal to 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter.
  • Participant has symptomatic CNS involvement of disease (does not apply to PCNSL participants in Part B).
  • Participant is on chronic systemic immunosuppressive therapy or corticosteroids (eg, prednisone or equivalent not to exceed 10 mg per day within the last 14 days) or participants with clinically significant graft-versus-host disease (GVHD).
  • Participant had prior autologous SCT less than or equal to3 months prior to starting CC 99282 and any treatment-related toxicity is unresolved (grade > 1).
  • Participant had prior allogeneic SCT with either standard or reduced intensity conditioning 6 months or less prior to starting CC-99282. If participant had prior allogeneic SCT > 6 months prior to the start of CC-99282, any treatment-related toxicity is unresolved (grade > 1).
  • Participant had major surgery less than or equal to 2 weeks prior to starting CC-99282. Participants must have recovered from any clinically significant effects of recent surgery
  • Prior radiotherapy within one month prior to starting study drug.
  • Known human immunodeficiency virus (HIV) infection.
  • Known chronic active hepatitis B or C virus (HBV/HCV) infection.
  • History of concurrent second cancers requiring active, ongoing systemic treatment.
  • Concurrent administration of strong CYP3A4/5 modulators
  • Other criteria may apply

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.